NF-kappa-B inhibitor alpha (NFKBIA) (NFKBIA)

NF-kappa-B inhibitor alpha (NFKBIA), also known as IκBα, is a critical regulator of the NF-kappa-B signaling pathway, which governs immune and inflammatory responses (UniProt P25963). Under normal physiological conditions, NFKBIA binds to NF-kappa-B dimers in the cytoplasm, masking their nuclear localization signals and preventing their translocation to the nucleus. Activation of the pathway by stimuli like TNF-alpha or IL-1 leads to the phosphorylation of NFKBIA by the IKK complex, triggering its ubiquitination and degradation by the 26S proteasome (PubMed 12748650). This degradation releases NF-kappa-B to enter the nucleus and activate the transcription of genes involved in cell survival and inflammation. In many cancers and inflammatory diseases, NFKBIA is either mutated or excessively degraded, leading to constitutive NF-kappa-B activity. Pharmacological intervention often involves the use of proteasome inhibitors like bortezomib or glucocorticoids like dexamethasone to stabilize NFKBIA levels and suppress pathological NF-kappa-B signaling (NCBI Gene 4792). The protein's role as a gatekeeper for NF-kappa-B makes it a central node in cellular stress responses and a significant focus for drug development in oncology and immunology (PubMed 11801734).

Other names

IkappaB-alphaIKBAMAD-3NFKBINuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha

NFKBIA inhibits the NF-kappa-B pathway by sequestering NF-kappa-B dimers in the cytoplasm. Therapeutic agents typically act by preventing the phosphorylation or proteasomal degradation of NFKBIA, thereby maintaining its inhibitory effect on NF-kappa-B-mediated transcription.